United States Biotechnology & Medical Research

Passage Bio Inc (PASG)

Track

Over the past 90 days, Passage Bio Inc. recorded one insider transaction, consisting of a purchase valued at approximately $206,101 by Lynx1 Capital Management LP on June 25, 2026. This activity follows the company's May 2026 results financiers, where it reported an earnings beat of 22.89%. The stock has declined 9.1% over the last quarter.
Ticker: PASG Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Passage Bio Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 25 Jun 2026
Value US$4,904,371.48 | Price 357.11 | Shares 42,654 (-13.2%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-29 2026-06-25 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
42,654 -13.2%
357.11
US$4,904,371 		42,654 -13.2% 357.11 US$4,904,371
2026-01-09 2026-01-09 PrS Proposed sale
3.4
Chou William

Officer

Officer
97,975
173.24
US$1,544,055 		97,975 173.24 US$1,544,055
2026-01-12 2026-01-08 S Sale
3.4
Chou William

PRESIDENT AND CEO

Executive Director
28,604 -15.0%
217.89
US$83,497 		28,604 -15.0% 217.89 US$83,497
2026-01-12 2026-01-08 S Sale
3.8
Borthwick Kathleen

CFO

Officer
2,062 -27.6%
18.44
US$38,022 		2,062 -27.6% 18.44 US$38,022
2025-09-15 2025-09-15 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
11,900 +1.9%
6.99
US$83,175 		11,900 +1.9% 6.99 US$83,175
2025-09-15 2025-09-12 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
19,783 +3.3%
6.99
US$138,299 		19,783 +3.3% 6.99 US$138,299
2025-09-15 2025-09-11 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
325 +0.1%
6.96
US$2,261 		325 +0.1% 6.96 US$2,261
2025-07-24 2025-07-24 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
66,423 +12.6%
5.71
US$379,455 		66,423 +12.6% 5.71 US$379,455
2025-07-24 2025-07-23 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
49,302 +10.4%
5.74
US$283,033 		49,302 +10.4% 5.74 US$283,033
2025-07-24 2025-07-22 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
13,123 +2.8%
5.44
US$71,338 		13,123 +2.8% 5.44 US$71,338
2025-07-21 2025-07-21 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
132,645
5.56
US$737,506 		132,645 5.56 US$737,506
2025-07-15 2025-07-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
53,293
6.79
US$361,859 		53,293 6.79 US$361,859
2025-07-07 2025-07-07 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
259,000
0.43
US$112,147 		259,000 0.43 US$112,147
2025-06-26 2025-06-26 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
213,257 -3.4%
0.33
US$70,375 		213,257 -3.4% 0.33 US$70,375
2025-06-26 2025-06-25 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
138,800 -2.2%
0.33
US$45,804 		138,800 -2.2% 0.33 US$45,804
2025-06-26 2025-06-24 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
231,600 -3.5%
0.35
US$81,060 		231,600 -3.5% 0.35 US$81,060
2025-06-24 2025-06-24 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
1,076,120
0.35
US$378,364 		1,076,120 0.35 US$378,364
2025-04-24 2025-04-24 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
68,195 -1.0%
0.32
US$21,822 		68,195 -1.0% 0.32 US$21,822
2025-04-24 2025-04-23 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
89,328 -1.3%
0.34
US$30,372 		89,328 -1.3% 0.34 US$30,372
2025-04-24 2025-04-22 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
78,049 -1.1%
0.34
US$26,537 		78,049 -1.1% 0.34 US$26,537
2025-04-17 2025-04-17 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
77,090 -1.1%
0.33
US$25,440 		77,090 -1.1% 0.33 US$25,440
2025-04-17 2025-04-16 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
61,638 -0.9%
0.33
US$20,341 		61,638 -0.9% 0.33 US$20,341
2025-04-17 2025-04-15 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
10,326 -0.1%
0.38
US$3,924 		10,326 -0.1% 0.38 US$3,924
2025-04-15 2025-04-15 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
787,179
0.38
US$301,490 		787,179 0.38 US$301,490
2025-02-12 2025-02-11 S Sale
3.8
Borthwick Kathleen

CFO

Officer
3,183 -7.2%
0.53
US$1,686 		3,183 -7.2% 0.53 US$1,686
2025-01-14 2025-01-14 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
79,024 -1.1%
0.60
US$47,414 		79,024 -1.1% 0.60 US$47,414
2025-01-14 2025-01-13 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
17,986 -0.3%
0.64
US$11,511 		17,986 -0.3% 0.64 US$11,511
2025-01-14 2025-01-10 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
126,209 -1.7%
0.66
US$83,298 		126,209 -1.7% 0.66 US$83,298
2025-01-08 2025-01-08 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
75,007 -1.0%
0.68
US$51,005 		75,007 -1.0% 0.68 US$51,005
2025-01-08 2025-01-07 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
52,536 -0.7%
0.71
US$37,301 		52,536 -0.7% 0.71 US$37,301
2025-01-08 2025-01-06 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
19,481 -0.3%
0.77
US$15,000 		19,481 -0.3% 0.77 US$15,000
2025-01-06 2025-01-06 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
1,140,740
0.83
US$945,673 		1,140,740 0.83 US$945,673
2024-12-31 2024-12-27 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
373,645 +4.2%
0.65
US$241,038 		373,645 +4.2% 0.65 US$241,038
2024-12-26 2024-12-20 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
230,321 -3.0%
0.60
US$138,193 		230,321 -3.0% 0.60 US$138,193
2024-12-11 2024-12-11 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
80 -0.0%
0.80
US$64 		80 -0.0% 0.80 US$64
2024-12-11 2024-12-10 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
8,015 -0.1%
0.80
US$6,412 		8,015 -0.1% 0.80 US$6,412
2024-12-11 2024-12-09 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
54,181 -0.7%
0.84
US$45,512 		54,181 -0.7% 0.84 US$45,512
2024-12-06 2024-12-06 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
20,903 -0.3%
0.82
US$17,140 		20,903 -0.3% 0.82 US$17,140
2024-12-06 2024-12-04 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
76,200 -1.0%
0.79
US$60,198 		76,200 -1.0% 0.79 US$60,198
2024-12-04 2024-12-04 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Stockholder

Large shareholder
2,985,518
0.89
US$2,657,111 		2,985,518 0.89 US$2,657,111
2024-12-04 2024-12-04 PrS Proposed sale
Worldwide Healthcare Trust PLC

Stockholder

Large shareholder
2,028,307
0.89
US$1,805,193 		2,028,307 0.89 US$1,805,193
2024-11-27 2024-11-27 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
29,300 +0.3%
0.67
US$19,663 		29,300 +0.3% 0.67 US$19,663
2024-11-27 2024-11-26 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
167,055 +1.9%
0.71
US$118,191 		167,055 +1.9% 0.71 US$118,191
2024-11-27 2024-11-25 B Purchase
4.1
Lynx1 Capital Management LP
Large shareholder
259,998 +3.1%
0.56
US$146,665 		259,998 +3.1% 0.56 US$146,665
2024-09-23 2024-09-19 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
39,300 -0.5%
0.71
US$27,903 		39,300 -0.5% 0.71 US$27,903
2024-09-18 2024-09-18 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
25,631 -0.3%
0.73
US$18,711 		25,631 -0.3% 0.73 US$18,711
2024-09-18 2024-09-17 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
111,400 -1.4%
0.73
US$81,322 		111,400 -1.4% 0.73 US$81,322
2024-09-18 2024-09-16 S Sale
2.6
ORBIMED ADVISORS LLC
Large shareholder
63,100 -0.8%
0.74
US$46,694 		63,100 -0.8% 0.74 US$46,694
2024-09-16 2024-09-16 PrS Proposed sale
Worldwide Healthcare Trust PLC

Owner
241,328
0.81
US$194,752 		241,328 0.81 US$194,752
2024-09-16 2024-09-16 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Owner
927,572
0.81
US$748,551 		927,572 0.81 US$748,551
2024-02-13 2024-02-13 S Sale
3.8
Borthwick Kathleen

SVP, INTERIM CFO

Officer
1,470 -4.9%
0.97
US$1,426 		1,470 -4.9% 0.97 US$1,426
2024-02-13 2024-02-13 S Sale
1.0
Forman Mark S

CHIEF MEDICAL OFFICER

Officer
1,638 -3.3%
0.97
US$1,589 		1,638 -3.3% 0.97 US$1,589
2024-01-03 2024-01-02 S Sale
3.8
Borthwick Kathleen

SVP, Interim CFO

Officer
10,672 -29.2%
0.91
US$9,712 		10,672 -29.2% 0.91 US$9,712
2024-01-03 2024-01-02 S Sale
1.0
Forman Mark S

Chief Medical Officer

Officer
15,813 -25.9%
0.91
US$14,390 		15,813 -25.9% 0.91 US$14,390
2024-01-03 2024-01-02 S Sale
0.6
Cale Edgar B.

GC & Corporate Secretary

Officer
15,813 -25.6%
0.91
US$14,390 		15,813 -25.6% 0.91 US$14,390
2023-08-01 2023-07-28 S Sale
3.6
King Simona

Chief Financial Officer

Officer
11,453 -32.3%
0.88
US$10,079 		11,453 -32.3% 0.88 US$10,079
2023-06-29 2023-06-28 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
575,195 +7.7%
0.84
US$483,164 		575,195 +7.7% 0.84 US$483,164
2023-06-29 2023-06-27 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
617,382 +9.0%
0.84
US$518,601 		617,382 +9.0% 0.84 US$518,601
2023-06-20 2023-06-16 S Sale
2.3
Fotopoulos Alexandros

Chief Technical Officer

Officer
4,052 -12.4%
0.93
US$3,778 		4,052 -12.4% 0.93 US$3,778
2023-04-20 2023-04-18 S Sale
3.6
King Simona

Chief Financial Officer

Officer
2,053 -50.0%
1.05
US$2,156 		2,053 -50.0% 1.05 US$2,156
2022-12-02 2022-12-01 PlS Planned sale
Kapadia Sandip
Non-Executive Director
5,000 -100.0%
1.19
US$5,964 		5,000 -100.0% 1.19 US$5,964
2022-11-25 2022-11-22 PlS Planned sale
2.3
Fotopoulos Alexandros

Chief Technical Officer

Officer
3,720 -15.5%
1.33
US$4,948 		3,720 -15.5% 1.33 US$4,948
2022-11-18 2022-09-19 S Sale
2.4
Toernsen Monika Maria

Chief Commercial Officer

Officer
1,681 -33.6%
1.51
US$2,539 		1,681 -33.6% 1.51 US$2,539
2022-05-05 2022-05-04 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
303,500 +4.6%
1.94
US$588,790 		303,500 +4.6% 1.94 US$588,790
2022-05-05 2022-05-03 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
221,500 +3.5%
1.93
US$427,495 		221,500 +3.5% 1.93 US$427,495
2022-03-23 2022-03-21 B Purchase
0.6
Goldsmith Bruce A

CEO and President

Executive Director
10,000 +167.1%
3.15
US$31,500 		10,000 +167.1% 3.15 US$31,500
2022-01-24 2022-01-20 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
369,100 +5.9%
5.42
US$2,000,522 		369,100 +5.9% 5.42 US$2,000,522
2022-01-20 2022-01-19 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
43,300 +0.7%
5.11
US$221,263 		43,300 +0.7% 5.11 US$221,263
2022-01-20 2022-01-18 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
114,700 +1.9%
5.46
US$626,262 		114,700 +1.9% 5.46 US$626,262
2022-01-20 2022-01-14 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
10,300 +0.2%
5.60
US$57,680 		10,300 +0.2% 5.60 US$57,680
2022-01-13 2022-01-13 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
41,800 +0.7%
5.52
US$230,736 		41,800 +0.7% 5.52 US$230,736
2022-01-13 2022-01-12 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
100,000 +1.7%
5.65
US$565,000 		100,000 +1.7% 5.65 US$565,000
2022-01-13 2022-01-11 B Purchase
2.6
ORBIMED ADVISORS LLC
Large shareholder
8,200 +0.1%
5.53
US$45,346 		8,200 +0.1% 5.53 US$45,346
2021-05-21 2021-05-21 PP Planned purchase
0.6
Goldsmith Bruce A

CEO and President

Executive Director
2,000 +50.2%
13.12
US$26,230 		2,000 +50.2% 13.12 US$26,230
2021-03-17 2021-03-15 PlS Planned sale
4.1
Romano Gary

Chief Medical Officer

Officer
1,617 -100.0%
21.86
US$35,350 		1,617 -100.0% 21.86 US$35,350
Explore more

More insider trading research around Passage Bio Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America